Mylan jacked up EpiPen prices in PBM kickbacks scheme, class action suit claims

Fierce Pharma -------- As if it wasn’t bad enough that Mylan's EpiPen faces declining sales and a global recall, the company now must contend with a class action lawsuit over its pricing. Filed Monday in federal court, the suit is the first to bring claims against Mylan under the federal Racketeer Influenced and Corrupt Organizations Act (RICO). What make this a RICO suit are allegations that Mylan paid hefty rebates to pharmacy benefits managers (PBMs) in return for favorable EpiPen treatment. Those PBMs included CVS Caremark, Express Scripts and UnitedHealth Group’s OptumRX, according to the suit, though none of them is named as a defendant. To learn more click on the picture below to read the article.